BIO Bio-Rad Laboratories, Inc. Class A

Price (delayed)

$538.51

Market cap

$16.06B

P/E Ratio

4.55

Dividend/share

N/A

EPS

$118.31

Enterprise value

$15.87B

Sector: Healthcare
Industry: Medical Devices
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Highlights

The price to earnings (P/E) is 95% lower than the 5-year quarterly average of 85.1 and 24% lower than the last 4 quarters average of 6.0
The EPS has soared by 81% from the previous quarter
The company's quick ratio fell by 49% YoY but it rose by 3.9% QoQ

Key stats

What are the main financial stats of BIO
Market
Shares outstanding
29.83M
Market cap
$16.06B
Enterprise value
$15.87B
Valuations
Price to earnings (P/E)
4.55
Price to book (P/B)
1.81
Price to sales (P/S)
6.72
EV/EBIT
3.49
EV/EBITDA
3.49
EV/Sales
6.67
Earnings
Revenue
$2.38B
EBIT
$4.55B
EBITDA
$4.55B
Free cash flow
$369.21M
Per share
EPS
$118.31
Free cash flow per share
$12.42
Book value per share
$297.36
Revenue per share
$80.09
TBVPS
$387.73
Balance sheet
Total assets
$12.02B
Total liabilities
$3.2B
Debt
$645.41M
Equity
$8.83B
Working capital
$1.34B
Liquidity
Debt to equity
0.07
Current ratio
2.36
Quick ratio
1.58
Net debt/EBITDA
-0.04
Margins
EBITDA margin
191.2%
Gross margin
55%
Net margin
147.9%
Operating margin
12.4%
Efficiency
Return on assets
36.3%
Return on equity
49.9%
Return on invested capital
54.9%
Return on capital employed
41.3%
Return on sales
191.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIO stock price

How has the Bio-Rad Laboratories stock price performed over time
Intraday
0%
1 week
4.25%
1 month
-8.17%
1 year
45.79%
YTD
45.53%
QTD
4.47%

Financial performance

How have Bio-Rad Laboratories's revenue and profit performed over time
Revenue
$2.38B
Gross profit
$1.31B
Operating income
$294.92M
Net income
$3.52B
Gross margin
55%
Net margin
147.9%
The net income has soared by 81% QoQ
The net margin has surged by 74% since the previous quarter
BIO's operating income is up by 21% since the previous quarter
BIO's operating margin is up by 17% since the previous quarter

Growth

What is Bio-Rad Laboratories's growth rate over time

Valuation

What is Bio-Rad Laboratories stock price valuation
P/E
4.55
P/B
1.81
P/S
6.72
EV/EBIT
3.49
EV/EBITDA
3.49
EV/Sales
6.67
The price to earnings (P/E) is 95% lower than the 5-year quarterly average of 85.1 and 24% lower than the last 4 quarters average of 6.0
The EPS has soared by 81% from the previous quarter
The equity has soared by 72% YoY and by 20% from the previous quarter
BIO's P/B is 4.7% below its 5-year quarterly average of 1.9
The stock's price to sales (P/S) is 87% more than its 5-year quarterly average of 3.6 and 24% more than its last 4 quarters average of 5.4
The revenue has grown by 3.8% from the previous quarter and by 3.3% YoY

Efficiency

How efficient is Bio-Rad Laboratories business performance
The ROS has soared by 73% from the previous quarter
The company's return on invested capital has surged by 59% QoQ
Bio-Rad Laboratories's ROA has soared by 59% from the previous quarter
The ROE has soared by 57% since the previous quarter

Dividends

What is BIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIO.

Financial health

How did Bio-Rad Laboratories financials performed over time
The total assets has soared by 67% year-on-year and by 19% since the previous quarter
BIO's total liabilities has surged by 56% year-on-year and by 16% since the previous quarter
The debt is 93% smaller than the equity
The equity has soared by 72% YoY and by 20% from the previous quarter
Bio-Rad Laboratories's debt to equity has decreased by 46% YoY and by 22% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.